Back to search

Article

Basis of narrow-spectrum activity of fidaxomicin on gut pathogen <i>Clostridioides difficile</i>

2022-01-17

Abstract excerpt

Fidaxomicin (Fdx) is widely used to treat Clostridioides difficile ( Cdiff ) infections (CDIs), but the molecular basis of its narrow-spectrum activity in the human gut microbiome remains enigmatic. CDIs are a leading cause of nosocomial deaths. Fdx, which inhibits RNA polymerase (RNAP), targets Cdiff with minimal effects on gut commensals, reducing CDI recurrence. Here, we present the cryo-electron microscopy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e69e096f-d316-5a43-a885-a90ae396ba6a
DOI
10.1101/2022.01.17.476619
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Basis of narrow-spectrum activity of fidaxomicin on gut pathogen <i>Clostridioides difficile</i>DOI 10.1101/2022.01.17.476619
Select a neighboring publication to make it the new centre.